Drug-resistant is a critical threat to public health, and bacterial carbonic anhydrases expressed by are potential new therapeutic targets to combat this pathogen. To further expand upon our recent reports of bacterial carbonic anhydrase inhibitors for the treatment of , our team has solved ligand-bound crystal structures of the FDA-approved carbonic anhydrase inhibitor acetazolamide, along with three analogs, in complex with the essential α-carbonic anhydrase isoform from . The structural data for the analogs presented bound to α-carbonic anhydrase supports the observed structure-activity relationship for inhibition with this scaffold against the enzyme. Moreover, the ligand-bound structures indicate differences in binding poses compared to those traditionally observed with the close human ortholog carbonic anhydrase II. These results present key differences in inhibitor binding between α-carbonic anhydrase and the human carbonic anhydrase II isoform.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841583 | PMC |
http://dx.doi.org/10.1021/acsmedchemlett.2c00471 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!